ISSN: 1838-7640Theranostics
Global reach, higher impact
Theranostics 2023; 13(10):3451-3466. doi:10.7150/thno.83405 This issue Cite
Research Paper
The landscape of abnormal pathway activation confers COVID-19 patients' molecular sequelae earlier than clinical phenotype
1. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China.
2. Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350108, Fujian Province, China.
3. The First Affiliated Hospital of Fujian Medical University, Fuzhou 350108, Fujian Province, China.
#These authors contributed equally.
Citation:
Zhang X, Sh Y, Dong J, Chen Z, Hong F. The landscape of abnormal pathway activation confers COVID-19 patients' molecular sequelae earlier than clinical phenotype. Theranostics 2023; 13(10):3451-3466. doi:10.7150/thno.83405. https://www.thno.org/v13p3451.htm
Other stylesAbstract
Rationale: The 2019 coronavirus disease (COVID-19) pandemic poses a significant threat to human health. After SARS-CoV-2 infection, major clinical concerns are organ damage and possible sequelae.
Methods: In this study, we analyzed serum multi-omics data based on population-level, including healthy cohort, non-COVID-19 and COVID-19 covered different severity cohorts. We applied the pseudo-SpatioTemporal Consistency Alignment (pST-CA) strategy to correct for individualized disease course differences, and developed pseudo-deterioration timeline model and pseudo-recovery timeline model based on the "severe index" and "course index". Further, we comprehensively analyzed and discussed the dynamic damage signaling in COVID-19 deterioration and/or recovery, as well as the potential risk of sequelae.
Results: The deterioration and course models based on the pST-CA strategy can effectively map the activation of blood molecular signals on cellular, pathway, functional and disease phenotypes in COVID-19 deterioration and throughout the disease course. The models revealed the neurological, cardiovascular, and hepatic toxicity present in SARS-CoV-2. The abundance of differentially expressed proteins and the activity of upstream regulators were comprehensively analyzed and evaluated to predict possible target drugs for SARS-CoV-2. On molecular docking simulation analysis, it was further demonstrated that blocking CEACAM1 is a potential therapeutic target for SARS-CoV-2.
Conclusions: Clinically, the risk of organ failure and death in COVID-19 patients rises with increasing number of infections. Individualized sequelae prediction for patients and assessment of individualized intervenable targets and available drugs in combination with the upstream regulator analysis results are of great clinical value.
Keywords: COVID-19, Sequelae, pST-CA, Serum multi-omics, Abnormal pathway activation
Citation styles
APA
Zhang, X., Sh, Y., Dong, J., Chen, Z., Hong, F. (2023). The landscape of abnormal pathway activation confers COVID-19 patients' molecular sequelae earlier than clinical phenotype. Theranostics, 13(10), 3451-3466. https://doi.org/10.7150/thno.83405.
ACS
Zhang, X.; Sh, Y.; Dong, J.; Chen, Z.; Hong, F. The landscape of abnormal pathway activation confers COVID-19 patients' molecular sequelae earlier than clinical phenotype. Theranostics 2023, 13 (10), 3451-3466. DOI: 10.7150/thno.83405.
NLM
Zhang X, Sh Y, Dong J, Chen Z, Hong F. The landscape of abnormal pathway activation confers COVID-19 patients' molecular sequelae earlier than clinical phenotype. Theranostics 2023; 13(10):3451-3466. doi:10.7150/thno.83405. https://www.thno.org/v13p3451.htm
CSE
Zhang X, Sh Y, Dong J, Chen Z, Hong F. 2023. The landscape of abnormal pathway activation confers COVID-19 patients' molecular sequelae earlier than clinical phenotype. Theranostics. 13(10):3451-3466.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.